PACB 1.8 (+1.69%)
US69404D1081Medical Diagnostics & ResearchDiagnostics & Research

Pacific Biosciences of California (PACB) Competitor Comparison

We are evaluating the key criteria listed to compare Pacific Biosciences of California (PACB) against its competitors in the Diagnostics & Research industry.

Total Revenue - PACB ranking 36 / 57

These are the competitors of Pacific Biosciences of California in the industry Diagnostics & Research ranked by total revenue
1. Thermo Fisher Scientific TMO
43.42B
2. Danaher DHR
29.57B
3. Laboratory Corp of America Holdings LH
15.07B
4. IQVIA Holdings IQV
14.86B
5. Quest Diagnostics DGX
9.3B
6. Icon ICLR
8.02B
7. Agilent Technologies A
6.83B
8. Syneos Health SYNH
5.42B
9. Illumina ILMN
4.46B
10. Charles River Laboratories CRL
4.22B
11. Mettler-Toledo MTD
3.91B
12. IDEXX Laboratories IDXX
3.59B
13. DexCom DXCM
3.4B
14. PerkinElmer PKI
3.31B
15. Waters WAT
3B
16. Exact Sciences EXAS
2.41B
17. Ortho Clinical Diagnostics Holdings OCDX
2.04B
18. Qiagen QGEN
1.96B
19. Medpace Holdings MEDP
1.78B
20. RadNet RDNT
1.58B
21. Lantheus Holdings LNTH
1.21B
22. Sotera Health SHC
990.64M
23. Natera NTRA
988.72M
24. Neogen NEOG
918.68M
25. Myriad Genetics MYGN
734.4M
26. NeoGenomics NEO
574.8M
27. Inotiv NOTV
572.43M
28. Guardant Health GH
535.78M
29. Bioventus BVS
502.76M
30. CareDx CDNA
297.14M
31. Fulgent Genetics FLGT
286.41M
32. Prenetics Global PRE
279.64M
33. Heska HSKA
254.89M
34. Twist Bioscience TWST
245.11M
35. Global Cord Blood CO
172.98M
36. Pacific Biosciences of California PACB
169.52M
37. Olink Holding OLK
158.93M
38. National Research NRC
148.72M
39. Trinity Biotech TRIB
72.42M
40. Personalis PSNL
70.53M
41. Neuronetics STIM
69.23M
42. MDxHealth MDXH
63.69M
43. Exagen XGN
51.62M
44. Biodesix BDSX
44.03M
45. Interpace Biosciences IDXG
38.26M
46. MaxCyte MXCT
38.05M
47. Enzo Biochem ENZ
31.76M
48. DarioHealth DRIO
23.55M
49. Psychemedics PMD
22.8M
50. Precipio PRPO
13.26M
51. Aspira Womens Health AWH
9.18M
52. Co-Diagnostics CODX
4.66M
53. Organovo Holdings ONVO
368K
54. Sera Prognostics SERA
330K
55. bioAffinity Technologies BIAF
321.49K
56. Anixa Biosciences ANIX
210K
57. SeqLL SQL
0

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.